Pfizer’s Loss Could Be Nabi’s Gain In Stop-Smoking Space
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II vaccine, unlike Chantix, does not cross blood-brain barrier.
You may also be interested in...
GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.
GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.
Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.